(Q80951687)
Statements
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer (English)
M Ruiz
J Salvador
J Bayo
M Lomas
A Moreno
M Valero
R Bernabé
D Vicente
J Jiménez
A Lopez-Ladrón